Manufactures IV fluid bottles and Small Volume Parenterals (SVP) for pharmaceutical and healthcare use. The SteriPort range uses ISBM (Injection Stretch Blow Moulding) technology to make two-port IV fluid bottles and contributes 42% of FY26 revenue; a third SteriPort line is being commissioned to roughly double annual capacity. The SVP portfolio covers inhalation and ophthalmic products. Materials are the largest cost line at 33.7% of revenue, with polymer price increases of 60-70% passed through via 5-6% selling price increases. FY26 revenue stood at INR288 crore with EBITDA of INR63 crore (22% margin) and PAT of INR15 crore. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. SteriPort (42%), SVP and other products. Sterile parenteral pharmaceutical manufacturing (LVP and SVP)
| ₹ crore · consolidated | FY26 |
|---|---|
| Revenue | 288 |
| EBITDA (ex other income) | 57 |
| margin % | 19.9 |
| Owners' profit | 15 |
| EPS, as reported (₹) | 4.33 |
| ROE % · ROCE % | 6.8 · 10.0 |
| Debt / equity (x) | 1.06 |
| Cash from operations | 48 |
| Capex | (80) |
| ₹ crore | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|
| Revenue | 65 | 71 | 74 | 77 | 69 |
| Profit before tax | 5 | 2 | 6 | 8 | 4 |
| Net profit | 4 | 1 | 5 | 6 | 3 |
| EPS (₹) | 1.22 | 0.35 | 1.35 | 1.61 | 0.85 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 3 Sept 2026 · Newspaper ad on physical share dematerialisation window | compliance | minimal | — | — |
| 2 Sept 2026 · New SteriPort production line commissioned at Kheda facility | capex operations | high | — | — |
| 25 Aug 2026 · Amanta Healthcare shares web link for FY26 Annual Report and AGM notice | compliance | minimal | — | — |
| 25 Aug 2026 · Newspaper ad for 31st AGM notice and e-voting details | compliance | minimal | — | — |
| 24 Aug 2026 · Amanta Healthcare FY26 Annual Report and 31st AGM Notice | compliance | low | — | — |
| 24 Aug 2026 · Notice of 31st AGM and Annual Report for FY 2025-26 | board shareholder meetings | medium | — | — |
| 24 Aug 2026 · Annual Report 2025-26 and 31st AGM Notice | results | high | — | — |
| 12 Aug 2026 · Newspaper clippings of AGM notice submitted to BSE and NSE | compliance | minimal | — | — |
| 8 Aug 2026 · Q1 FY27 earnings call: revenue up 5%, margin expansion guided | investor communications | medium | — | — |
| 8 Aug 2026 · Amanta Healthcare Q1 FY27 IPO Funds Utilization Monitoring Report | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| 16.4 |
| 17.2 |
| 7.2 |
| 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 47.5 | 28.9 | 129 of 169 | 24% |
| P/B | 3.5 | 3.3 | 89 of 163 | 46% |
| ROCE | 5.1 | 10.8 | 123 of 183 | 33% |
| ROE | 6.8 | 10.4 | 112 of 171 | 35% |
| Debt / Equity | 1.1 | 0.1 | 161 of 171 | 6% |
| EBITDA margin | 22.1 | 17.5 | 67 of 165 | 60% |
| Revenue growth | 5.3 | 16.3 | 113 of 161 | 30% |
| Profit growth | (5.6) | 30.9 | 110 of 158 | 31% |
| Market cap | 768 | 839 | 94 of 182 | 49% |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
